Cover Image
Market Research Report
Product code 
1075872

Alzheimer Drugs Market - Forecast(2022 - 2027)

Published: | IndustryARC | 111 Pages | Delivery time: 2-3 business days

Price

Back to Top
Alzheimer Drugs Market - Forecast(2022 - 2027)
Published: February 22, 2022
IndustryARC
Content info: 111 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Alzheimer's Drugs Market size in 2019 is estimated to be $3.5 billion, growing at a CAGR of 6.8% during the forecast period 2022-2027. Alzheimer's is a progressive neurological disease and most common form of dementia with symptoms includes memory loss and destroy thinking skills, difficulties with problem-solving or language. The symptoms of Alzheimer's disease develop slowly for many years and eventually become more severe over a time. Increasing prevalence of the Neurological disorder in the geriatric population and rising aging population across the globe are the major factors driving the growth of the market. Moreover, growing awareness about treatment of Alzheimer's disease across the globe further enhance the overall market demand for Alzheimer's Drugs during the forecast period 2022-2027.

Report Coverage

The report: "Alzheimer's Drugs Market - Forecast (2022-2027)", by Industry ARC, covers an in-depth analysis of the following segments of the Alzheimer's Drugs Market:

By Drug Class : Cholinergic, Memantine, Combined drug, and Other drugs.

By Distribution Channel : Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

By Geography : North America, Europe, Asia-Pacific, and Rest of the World.

Key Takeaways

In 2019, North America dominates the Alzheimer's Drugs Market owing to increasing prevalence of the neurological disorder among the geriatric population here.

Increasing the aging population is driving the market growth of Alzheimer's Drugs Market.

Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Alzheimer's Drugs Market report.

Difficulty involved in the early diagnosis of indication of Alzheimer's disease are challenging the growth of the market.

Alzheimer's Drugs Market Segment Analysis - Drug Class

Based on the Drug Class, Alzheimer's Drugs Market is segmented into Cholinergic, Memantine, Combined drug, and other drugs. The Memantine segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 5.4% during the forecast period 2022-2027. This is mainly owing to growing purchasing power and disposable income of the people that are contributing to increased sales of this drug class. Moreover, it is used to treat symptoms like confusion, improves memory and brain function, which further drives the market.

Alzheimer's Drugs Market Segment Analysis - Distribution Channel

Based on the Distribution channel, Alzheimer's Drugs Market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In 2019, Hospital Pharmacies held the largest share in the Alzheimer's Drugs Market. This is mainly owing to availability of cost-effective medicine for the treatment of Alzheimer's which driving the market. Most of the Alzheimer's drugs are prescription only, this is contributing to the high sales of these drugs through hospital pharmacies. However, online pharmacies are poised to grow the fastest over the forecast period 2022-2027. This is owing to increased adoption of online pharmacies and benefits offered by online channels such as ease of availability and convenience.

Alzheimer's Drugs Market Segment Analysis - Geography

In 2019, North America dominated the Alzheimer's Drugs market share accounting for XX% of the market. This is mainly owing to increasing prevalence of the neurological disorder in the geriatric population in this region. According to U.S. Food and Drug Administration FDA, in 2017, more than 5.8 Million American have Alzheimer's which increases the demand of Alzheimer's Drugs Market.

However, the Asia-Pacific region is projected to be the fastest-growing during the forecast period 2022-2027. This is owing to increasing awareness among people about treatment of Alzheimer's disease.

Alzheimer's Drugs Market Drivers

Increasing Prevalence of neurological disorder

According to World Health Organization (WHO), around 50million people have dementia, which is common form of Alzheimer's disease and there are 10 million new cases every year. The high prevalence of such diseases drive the growth of these drugs as well. Thus, increasing prevalence of the neurological disorder in the geriatric population across the globe is driving the growth of Alzheimer's Drugs market.

Growing Awareness about Alzheimer's Treatment

Growing awareness among the people about treatment of Alzheimer's disease in worldwide is driving the growth of the market. Moreover, people are also gaining awareness on the various innovative treatment options and this is further contributing to the growth of Alzheimer's Drugs Market.

Alzheimer's Drugs Market Challenges

Difficulty involved in the early diagnosis of indication of Alzheimer's disease is challenging the growth of the market. Moreover high cost of R&D activities for drug development is further restraining its market growth during the forecast period 2022-2027.

Alzheimer's Drugs Industry Outlook

Product launches, Merger & Acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Alzheimer's Drugs Market. Alzheimer's Drug top 10 companies are Johnson & Johnson Services, Bayer AG, Ono Pharmaceutical Co. Ltd, Eli Lilly and Company, GE Healthcare, Roche AG, Genentech Inc., AB Science, AC Immune and Biogen.

Developments:

On August 2020, Biogen announced FDA acceptance of the Biologics License Application (BLA) for Aducanumab, an investigational treatment for Alzheimer's disease.

Product Code: HCR 0112

Table of Contents

1. Alzheimer's Drugs Market Overview

  • 1.1 Definitions and Scope

2. Alzheimer's Drugs Market - Executive Summary

  • 2.1 Market Size and Key Trends
  • 2.2 Key trends by Drug Class
  • 2.3 Key trends by Distribution Channel
  • 2.4 Key trends by Geography

3. Alzheimer's Drugs Market Landscape

  • 3.1 Market Share Analysis - Key Companies
  • 3.2 Product Benchmarking - Key Companies
  • 3.3 Financial Analysis - Key Companies
  • 3.4 Patent Analysis
  • 3.5 Pricing Analysis

4. Alzheimer's Drugs Market Forces

  • 4.1 Market Drivers
  • 4.2 Market Constraints/Challenges
  • 4.3 Porters Five Force Model
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Powers of Customers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Rivalry Among Existing Players
    • 4.3.5 Threat of Substitutes

5. Alzheimer's Drugs Market - Strategic Analysis

  • 5.1 Value Chain Analysis
  • 5.2 Opportunities Analysis
  • 5.3 Market Life Cycle

6. Alzheimer's Drugs Market - By Drug Class (Market Size -$Million/$Billion)

  • 6.1 Cholinergic
  • 6.2 Memantine
  • 6.3 Combined drug
  • 6.4 Other drugs

7. Alzheimer's Drugs Market - By Distribution Channel (Market Size -$Million/$Billion)

  • 7.1 Hospital Pharmacy
  • 7.2 Retail Pharmacy
  • 7.3 Online Pharmacy

8. Alzheimer's Drugs Market- By Geography (Market Size -$Million/$Billion)

  • 8.1 North America
    • 8.1.1 U.S.
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 U.K.
    • 8.2.2 Germany
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Spain
    • 8.2.6 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 South Korea
    • 8.3.4 India
    • 8.3.5 Australia & New Zealand
    • 8.3.6 Rest of Asia-Pacific
  • 8.4 Rest of the World
    • 8.4.1 Middle East
    • 8.4.2 Africa
    • 8.4.3 South America

9. Alzheimer's Drugs Market - Entropy

10. Alzheimer's Drugs Market Company Analysis

  • 10.1 Company Revenue, Products, M&A, Developments
  • 10.2 Company 1
  • 10.3 Company 2
  • 10.4 Company 3
  • 10.5 Company 4
  • 10.6 Company 5
  • 10.7 Company 6
  • 10.8 Company 7
  • 10.9 Company 8
  • 10.10 Company 9
  • 10.11 Company 10

"*Financials for private companies would be provided on a best efforts basis".